Doylestown, PA (PRWEB) September 18, 2014
N-Zyme Scientifics LLC achieved a major developmental milestone this month by successfully launching its first product a mere 8 months after company startup. Its novel product PNGase F PRIME™ is a high performance glycan release enzyme used in the “Biologics” industry for discovery and quality assurance, glycobiology research, and the basis for tissue pathology on Mass Spec devices. PRIME™ is being sold by Bulldog Bio (Portsmouth, NH) for the North American market (PNGase F PRIMETM). N-Zyme is currently evaluating several companies to represent the product in Europe and Asia.
Dr. David Hamlin, Founder and CEO of N-Zyme Scientifics, stated “Our product has already intriqued the glycobiology community with remarkable results, drastically shortening the total time to analyze samples of interest while releasing glycoforms previously not typically seen with other PNGases.“
Opportunities for applications as a novel diagnostic step in cancer and inflammatory disease identification are inherently possible and the company invites additional collaborations with scientists, pharmacology and medical diagnostic companies towards their interests in this novel enzyme.
About N-Zyme Scientifics
N-Zyme Scientifics LLC is focused on the planned commercialization of a recently discovered key method of producing a high-performance PNGase F for the technical, biotech and Pharma markets. (http://www.N-Zymesci.com)
About Bulldog Bio
Bulldog Bio Incorporated is a privately held company headquartered in Portsmouth, NH, that distributes tools to Life Science researchers. Please visit http://www.bulldog-bio.com for more information about the company and its products. (http://www.bulldog-bio.com)
For Bulldog Bio:
Ella Fontaine, V.P. of Communications, +1 603-570-4248, ella.fontaine(at)bulldog-bio.com
For N-Zyme Scientifics:
Dr. David Hamlin, Founder and CEO, +1-215-378-2550, dahamlin(at)n-zymesci.com